EFFICACY AND SAFETY OF CEFIXIME IN THE TR EATMENT OF UTI IN MYELOMENINGOCELE PATIENTS

28 myelomeningocele patients (aged 2-30 years) with clinical symptoms of acute UTI participated in this open uncontrolled clinical trial at the Orthopedic University Hospital of Heidelberg (Dir.: Prof. Dr. H. C otta). 4 patients were treated with 200 mg cefixime tablets bid, 24 pa tients received 4 mg/kg body weight cefixime suspension bid, according to age and weight of the patients. The duration of treatment was 6-10 days. Clinical and microbiological examinations were carried out befo re therapy as well as 1 day and 5 to 9 days after the end of treatment . The data of 25 patients could be evaluated for bacteriological and c linical efficacy. 5-9 days after treatment in 22 patients (88%) comple te recovery was stated. In 3 patients a reinfection occured. In 24 pat ients (96%) the baseline pathogens were eliminated under cefixime ther apy. 5-9 days after the end of treatment in 3 patients reinfection was observed. Clinical side effects could be detected in 1 patient (vomit ing). These results indicate that the oral cephalosporin cefixime is e fficient and well tolerated in complicated UTI of myelomeningocele pat ients.